AbbVie reaches agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ELAHERE® in Platinum-Resistant Ovarian Cancer
AbbVie reaches agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ELAHERE® in Platinum-Resistant Ovarian Cancer |
| [21-October-2026] |
MONTREAL, Oct. 21, 2026 /CNW/ -- AbbVie is pleased to announce that negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) have successfully been completed for ELAHERE® (mirvetuximab soravtansine for injection), and that a Letter of Intent (LOI) has been signed by both parties.
Ovarian cancer is the leading cause of death from gynecological cancers in Canada.1 In 2026, an estimated 3,000 individuals were diagnosed. Most are diagnosed at an advanced stage, and many eventually develop platinum-resistant disease, a difficult-to-treat form of the disease that can leave women with limited treatment options.4 The burden of ovarian cancer is also a women's health equity issue. Women across Canada rely on having equitable access to meaningful advances in care, regardless of where they live. Continued collaboration across the healthcare system will be important to help translate innovation into timely access for eligible patients. ELAHERE® represents an important innovation for this patient population. It is the first novel targeted monotherapy to demonstrate statistically significant and clinically meaningful improvements in overall survival compared to single agent chemotherapy alone for FRα-positive patients with platinum-resistant ovarian cancer.2 ELAHERE® is an antibody-drug conjugate (ADC) indicated for the treatment of folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens.2,3 The conclusion of pCPA negotiations represents an important milestone in the reimbursement process and brings eligible women one step closer to potential access to ELAHERE® through provincial and territorial public drug plans. Following the completion of pCPA negotiations, AbbVie looks forward to continued collaboration with provincial and territorial governments and other key stakeholders to support timely and equitable public reimbursement of ELAHERE® for individuals with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. Statements "We're pleased to have reached an agreement with AbbVie for ELAHERE® for the treatment of people with FRα-positive platinum-resistant ovarian, fallopian tube, or peritoneal cancer. This is a testament to our shared, unwavering commitment to supporting the accessibility and affordability of clinically effective treatments for people who need them." "For women living with platinum-resistant ovarian cancer, time matters. The completion of pCPA negotiations is an encouraging step forward and brings eligible patients closer to accessing a new treatment through public drug plans. We remain committed to continued collaboration with stakeholders to help support timely provincial and territorial listings and equitable access to treatment for women across Canada." "Platinum-resistant ovarian cancer remains challenging to treat, and options for women living with this disease have historically been limited. Progress towards access to innovative therapies is essential to translating scientific advancements into meaningful benefits for patients and their families." "Every woman with platinum-resistant ovarian cancer deserves timely access to promising new treatment options. We thank our partners in the oncology community for understanding the urgency and celebrate this critical step forward for these women and their families." About Ovarian Cancer About ELAHERE® 1 About AbbVie in Oncology About AbbVie _____________________________________ SOURCE AbbVie Canada | ||
Company Codes: NYSE:ABBV |
